Literature DB >> 34083044

CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations.

Mohammad Mahmoudi Gomari1, Marziye Farsimadan2, Neda Rostami3, Zahra Mahmoudi1, Mahmood Fadaie4, Ibrahim Farhani5, Parastoo Tarighi6.   

Abstract

Among cell surface markers, CD44 is considered the main marker for identifying and isolating the cancer stem cells (CSCs) among other cells and has attracted significant attention in a variety of research areas. Many studies have shown the essential roles of CD44 in initiation, metastasis, and tumorigenesis in different types of cancer; however, the validity of CD44 as a therapeutic or diagnostic target has not been fully confirmed in some other studies. Whereas the association of specific single nucleotide polymorphisms (SNPs) in the CD44 gene and related variants with cancer risk have been observed in clinical investigations, the significance of these findings remains controversial. Here, we aimed to provide an up-to-date overview of recent studies on the association of CD44 polymorphisms and its variants with different kinds of cancer to determine whether or not it can be used as an appropriate candidate for cancer tracking.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD44; Cancer marker; Cancer prognosis; Single nucleotide polymorphism

Year:  2021        PMID: 34083044     DOI: 10.1016/j.mrrev.2021.108374

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

Review 1.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

Review 2.  The immune microenvironment in gastric adenocarcinoma.

Authors:  Yana Zavros; Juanita L Merchant
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-14       Impact factor: 73.082

3.  Genetic Variants miR-126, miR-146a, miR-196a2, and miR-499 in Polycystic Ovary Syndrome.

Authors:  R Li; Y Yu; S O Jaafar; B Baghchi; M Farsimadan; I Arabipour; H Vaziri
Journal:  Br J Biomed Sci       Date:  2022-01-07       Impact factor: 2.432

4.  MicroRNA Variants miR-27a rs895819 and miR-423 rs6505162, but not miR-124-1 rs531564, are Linked to Endometriosis and its Severity.

Authors:  S O Jaafar; J O Jaffar; S A Ibrahim; K K Jarjees
Journal:  Br J Biomed Sci       Date:  2022-01-07       Impact factor: 2.432

5.  SARS-CoV-2 spike evolutionary behaviors; simulation of N501Y mutation outcomes in terms of immunogenicity and structural characteristic.

Authors:  Neda Rostami; Edris Choupani; Yaeren Hernandez; Seyed S Arab; Seyed M Jazayeri; Mohammad M Gomari
Journal:  J Cell Biochem       Date:  2021-11-15       Impact factor: 4.480

6.  Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.

Authors:  Zhuolun Sun; Tengcheng Li; Chutian Xiao; Shaozhong Zou; Mingxiao Zhang; Qiwei Zhang; Zhenqing Wang; Hailun Zhan; Hua Wang
Journal:  World J Surg Oncol       Date:  2022-04-14       Impact factor: 2.754

7.  Characterization of folic acid-functionalized PLA-PEG nanomicelle to deliver Letrozole: A nanoinformatics study.

Authors:  Neda Rostami; Reza Davarnejad
Journal:  IET Nanobiotechnol       Date:  2021-11-23       Impact factor: 2.050

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.